phrykt

NRX Pharmaceuticals, Inc. (NRXP): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of NRXP were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling NRX Pharmaceuticals

From the latest filings

Overall: more buying than selling. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns NRXP

47 funds and institutions reported NRXP shares worth $47.6M at the end of Q2 2026, about 35% of the company. The largest holder is B Group, Inc. with 12.4%.

Funds and institutions (13F) 35%Everyone else 65%

10 largest owners, by share of the company

B Group, Inc.12.4%
Vanguard Capital Management LLC4.9%
Ameriprise Financial Inc2.8%
Balyasny Asset Management L.P.2.7%
Citadel Advisors LLC2.1%
AdvisorShares Investments LLC2.0%
Commonwealth Equity Services, LLC1.4%
UBS Group AG1.3%
Geode Capital Management, LLC1.0%
BlackRock, Inc.0.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
B Group, Inc.4.09M12.37%$16.7M+36%
Vanguard Capital Management LLC1.62M4.89%$6.6M+39%
Ameriprise Financial Inc928,7282.81%$3.8MNew
Balyasny Asset Management L.P.893,8642.70%$3.7MNew
Citadel Advisors LLC680,0432.06%$2.8MNew
AdvisorShares Investments LLC659,0181.99%$2.7M+57%
Commonwealth Equity Services, LLC454,4181.37%$1.9M+14%
UBS Group AG423,1151.28%$1.7M+1577%
Geode Capital Management, LLC314,6590.95%$1.3M+1%
BlackRock, Inc.220,4600.67%$902K+123%
Marshall Wace, LLP194,5800.59%$796KNew
Vanguard Fiduciary Trust Co182,7180.55%$747K+8%
Jane Street Group, LLC119,0180.36%$487K+170%
Bleakley Financial Group, LLC117,2160.35%$479KNo change
State Street Corp116,0840.35%$475K+33%
Hrt Financial LP100,7240.30%$411KNew
Northern Trust Corp62,9510.19%$257K+45%
Chicago Partners Investment Group LLC46,3880.14%$191K+35%
Quadrature Capital Ltd43,6050.13%$178KNew
One Wealth Management Investment & Advisory Services, LLC43,3090.13%$177KNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No NRXP insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

NRXP short interest

Very high short interest. 24.2% of NRXP shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 124%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 10.46M NRXP shares were sold short, 24.2% of the shares outstanding, up 5.1% from the report before. At the average daily volume of 2.29M shares, buying them all back would take about 4.6 trading days (days to cover).

Shares short, % of all shares

24.2%May 15Oct 3025.7%

Days to cover

4.6May 15Oct 3018.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202610.46M24.16%+5%2.29M4.6
Oct 15, 20269.95M22.98%+2%593,63216.8
Sep 30, 20269.79M22.62%+0%700,44314.0
Sep 15, 20269.77M22.57%+5%600,59616.3
Aug 31, 20269.30M21.47%+7%795,23811.7
Aug 14, 20268.67M20.03%+32%1.50M5.8
Jul 31, 20266.55M19.82%+6%863,8257.6
Jul 15, 20266.20M18.74%+15%838,0617.4
Jun 30, 20265.40M16.32%-6%1.01M5.4
Jun 15, 20265.71M17.27%+15%1.72M3.3
May 29, 20264.98M15.05%+7%1.65M3.0
May 15, 20264.67M14.13%+6%1.12M4.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

NRX Pharmaceuticals company events

NRX Pharmaceuticals filed 17 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing, auditor). The latest was on Nov 2, 2026.

  1. Nov 2, 2026AnnouncementShared information with investors. Filing
  2. Oct 16, 2026AnnouncementThe board of directors of NRx Pharmaceuticals, Inc. established December 17, 2026 as the date of the 2026 Annual Meeting of Stockholders and set October 28, 2026 as the record date for determining stockholders entitled to vote at the 2026 Annual Meeting. Filing
  3. Oct 5, 2026AgreementNRx Defense Systems, Inc., a subsidiary of NRx Pharmaceuticals, Inc., entered into a prime contract with Defense Advanced Research Projects Agency pursuant to which NRx Defense was awarded a contract to conduct the Synaptic Plasticity Augmented Rapid Circuit Stimulation clinical trial. Filing
  4. Sep 16, 2026AnnouncementNRx Pharmaceuticals, Inc. issued a press release announcing that it has received a written communication from the Director of Regulatory Operations of the FDA Office of Generic Drugs advising the Company that the amendment to its Abbreviated New Drug Application (ANDA), previously classified as a… Filing
  5. Sep 14, 2026AnnouncementShared information with investors. Filing
  6. Aug 17, 2026ResultsReleased financial results. Filing
  7. Aug 7, 2026AnnouncementShared information with investors. Filing
  8. Jul 22, 2026AnnouncementIn April 2026, NRx Pharmaceuticals, Inc. announced the incorporation of NRx Defense Systems, Inc., a Florida-based research and development subsidiary charged with the development of neuroplastic treatments that combine D-cycloserine with Transcranial Magnetic Stimulation under robotic-enabled… Filing
  9. Jun 4, 2026AgreementEntry into a Definitive Material Agreement. Filing
  10. Jun 2, 2026AnnouncementNRx Pharmaceuticals, Inc. issued a press release announcing that it intends to offer shares of its common stock, par value $0.001 per share in an underwritten public offering. Filing
  11. Mar 24, 2026LeadershipAt the 2025 Annual Meeting, the Company’s stockholders approved the Amendment No:1 to the Omnibus Incentive Plan to increase the annual “evergreen” share reserve under the Omnibus Incentive Plan. Filing
  12. Feb 17, 2026AnnouncementNRx Pharmaceuticals, Inc. issued a press release regarding a path to a new drug application with real world data and broader proposed indication for NRX-100 (ketamine) Following Type C FDA Meeting. Filing
  13. Feb 17, 2026AnnouncementNRx Pharmaceuticals, Inc. filed a prospectus supplement for an aggregate of $20 million of the Company’s shares of common stock, par value $0.001 per share, issuable pursuant to that certain At-The-Market Offering Agreement, as amended, with H.C. Wainwright & Co., LLC, dated August 14, 2023. Filing
  14. Feb 2, 2026LeadershipThe Board of Directors of the Company appointed Joseph M. Casper, age 75, as the Chief Operating Officer of the Company, effective January 27, 2026. Filing
  15. Jan 16, 2026ListingThe Company received a letter from the Listing Qualifications Staff of the Nasdaq notifying the Company that it is no longer in compliance with Nasdaq Listing Rules, which requires the Company to hold an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end. Filing
  16. Dec 29, 2025AnnouncementShared information with investors. Filing
  17. Nov 26, 2025AuditorChanges in Registrant ’ s Certifying Accountant. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

NRX Pharmaceuticals financials

Famous investors that hold NRXP

3 of the 50 well-known investors we track reported holding NRXP in their latest 13F filing. The largest position is Ken Griffin's, worth $2.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026746,635$2.2M0.0%+10%
Israel Englander · Millennium ManagementQ3 202642,061$123K0.0%+242%
Jim Simons · Renaissance TechnologiesQ3 202612,300$35.9K0.0%-68%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about NRX Pharmaceuticals, Inc. (NRXP) stock

Who owns the most NRXP stock?

The largest reported owner of NRX Pharmaceuticals, Inc. (NRXP) is B Group, Inc., with 12.4% of the company. In total, 47 funds and institutions reported holding NRXP at the end of Q2 2026, together about 35% of the shares. See the largest owners.

Are NRXP insiders buying or selling?

No NRXP insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in NRXP?

As of Oct 30, 2026, 10.46M NRXP shares were sold short, 24.2% of the shares outstanding, up 5.1% from the report before. At the average daily volume of 2.29M shares, buying them all back would take about 4.6 trading days (days to cover). See the history.

Which famous investors hold NRXP?

3 of the 50 well-known investors we track reported NRXP in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $2.2M. See all holders.

Executive pay

NRX Pharmaceuticals's chief executive was paid a total of $885K for the year ended Dec 31, 2025, up 12% from $790K the year before. In the last 12 months, NRX Pharmaceuticals's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$885KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.1MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.